Burger King Introduces Mozzarella Fries: A New Spin on an Old Favorite 
McDonald’s Rolls Out $5 Meal Deals to Emphasize Affordability Amid Rising Costs 
Semaglutide's Benefits Beyond Weight Loss: New Insights from the SELECT Trial 
McDonald's Faces Backlash Over $5 Meal Deal: Customers Call It 'Skimpy' 
Nike vs. Adidas: Anthony Edwards’ and Wembanyama’s Sneakers Soar in Popularity 
Why banks consider renewable energy to be a riskier investment than fossil fuels 
PUMA Welcomes AC Milan Star Theo Hernández to the Family 
Cancer drug pollution is a growing global concern 
Burger King’s Largest Franchisee Carrols, Acquired by RBI for $1 Billion, $500M Revamp 
Dolly Parton Serves Up Sweetness with Krispy Kreme Collaboration 
Shein's Potential London IPO Could Revitalize LSE Amid Geopolitical Tensions 
BYD Launches Shark Hybrid Pickup in Mexico, Eyes New Factory Amid US Tariff Hike 
Converse Faces Job Cuts as Nike Aims for $2 Billion in Cost Savings 
From Burger King to McDonald’s: Fast-Food Prices Surge Dramatically in Recent Years 
LEXINGTON, Mass., Jan. 26, 2016 -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that it will release its 2015 fourth quarter and year-end financial results after the market closes on Tuesday, February 16, 2016. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Tuesday, February 16, 2016, to discuss the financial results and other business developments.
Interested parties may access the live call via telephone by dialing 1-877-407-4018 (U.S.) or 1-201-689-8471 (International). To listen to the live call via T2 Biosystems' website, go to www.t2biosystems.com, in the Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call in the Events & Presentations section of the website.
About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. The T2Candida Panel was cleared for marketing by the U.S. Food and Drug Administration (FDA) in September 2014 for the detection of sepsis causing Candida. T2Candida Panel performance was established in adult subjects. T2Candida Panel performance in neonates, infants, and pediatric patients has not been established. For more information, please visit www.t2biosystems.com.
Media Contact: Susan Heins, Pure Communications [email protected] 864-286-9597 Investor Contact: Matt Clawson, Pure Communications [email protected] 949-370-8500
